Worsening of kidney function in patients with atrial fibrillation and chronic kidney disease: evidence from the real-world CALLIPER study

References

• Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.
   PubMed Web of Science ®Google Scholar
• Turakhia MP, Conference Participants, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Eur Heart J. 2018;39(24):2314–2325.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22(8):983–988.
   PubMed Web of Science ®Google Scholar
• Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–221.
   PubMed Web of Science ®Google Scholar
• Zoni-Berisso M, Lercari F, Carazza T, et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014;6:213–220.
   PubMed Web of Science ®Google Scholar
• Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127(5):569–574.
   PubMed Web of Science ®Google Scholar
• Bansal N, Xie D, Tao K, et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol. 2016;11(7):1189–1196.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158(4):629–636.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Liu P, Quinn RR, Lam NN, et al. Progression and regression of chronic kidney disease by age among adults in a population-based cohort in Alberta, Canada. JAMA Netw Open. 2021;4(6):e2112828.
   PubMed Web of Science ®Google Scholar
• Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
   PubMed Web of Science ®Google Scholar
• Seyed Ahmadi S, Svensson AM, Pivodic A, et al. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish Cohort Study. Cardiovasc Diabetol. 2020;19(1):9.
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GYH, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367(7):625–635.
   PubMed Web of Science ®Google Scholar
• Roldán V, Marín F, Fernández H, et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111(8):1159–1164.
   PubMed Web of Science ®Google Scholar
• Masson P, Kelly PJ, Craig JC, et al. Risk of stroke in patients with ESRD. CJASN. 2015;10(9):1585–1592.
   PubMed Web of Science ®Google Scholar
• Weis L, Metzger M, Haymann JP, et al. Renal function can improve at any stage of chronic kidney disease. PLOS One. 2013;8(12):e81835.
   PubMed Web of Science ®Google Scholar
• Ku E, Hsu RK, Johansen KL, et al. Recovery of kidney function after dialysis initiation in children and adults in the US: a retrospective study of United States renal data system data. PLOS Med. 2021;18(2):e1003546.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Willems BAG, Vermeer C, Reutelingsperger CPM, et al. The realm of vitamin K dependent proteins: shifting from coagulation toward calcification. Mol Nutr Food Res. 2014;58(8):1620–1635.
   PubMed Web of Science ®Google Scholar
• Peeters FECM, Dudink EAMP, Kimenai DM, et al. Vitamin K antagonists, non-vitamin K antagonist oral anticoagulants, and vascular calcification in patients with atrial fibrillation. TH Open. 2018;2(4):e391–e398.
   PubMedGoogle Scholar
• Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011;80(2):181–189.
   PubMed Web of Science ®Google Scholar
• Brodsky S, Eikelboom J, Hebert LA. Anticoagulant-related nephropathy. J Am Soc Nephrol. 2018;29(12):2787–2793.
   PubMed Web of Science ®Google Scholar
• de Aquino Moura KB, Behrens PMP, Pirolli R, et al. Anticoagulant-related nephropathy: systematic review and meta-analysis. Clin Kidney J. 2019;12(3):400–407.
   PubMed Web of Science ®Google Scholar
• Rizk DV, Warnock DG. Warfarin-related nephropathy: another newly recognized complication of an old drug. Kidney Int. 2011;80(2):131–133.
   PubMed Web of Science ®Google Scholar
• Levy DS, Grewal R, Le TH. Vitamin K deficiency: an emerging player in the pathogenesis of vascular calcification and an iatrogenic consequence of therapies in advanced renal disease. Am J Physiol Renal Physiol. 2020;319(4):F618–F623.
   PubMed Web of Science ®Google Scholar
• Washam JB, Holmes DN, Thomas LE, et al. Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from ORBIT-AF. J Am Heart Assoc. 2018;7(18):e008928.
   PubMed Web of Science ®Google Scholar
• Yao X, Tangri N, Gersh B, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. Am J Cardiol. 2017;70(21):2621–2632.
   Web of Science ®Google Scholar
• Coleman CI, Kreutz R, Sood N, et al. Rivaroxaban's impact on renal decline in patients with nonvalvular atrial fibrillation: a US MarketScan claims database analysis. Clin Appl Thromb Hemost. 2019;25:107602961986853.
   Web of Science ®Google Scholar
• Bonnemeier H, Kreutz R, Kloss S, et al. Comparative safety and effectiveness of non-vitamin-K oral anticoagulants vs phenprocoumon in patients with non-valvular atrial fibrillation and renal disease – results from the RELOADED study. Eur Stroke J. 2019;4(1_suppl):1–860.
   Google Scholar
• Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) Prescribing Information. Titusville, NJ: USA; January 2021. [cited 8 June 2021] Available from: http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf.
   Google Scholar
• Bayer AG. Xarelto (rivaroxaban) Summary of Product Characteristics. Berlin: Germany; 2 February 2021. [cited 10 January 2022] Available from: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf.
   Google Scholar
• Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560–566.
   PubMed Web of Science ®Google Scholar
• Inohara T, Holmes DN, Pieper K, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart. 2020;106(5):358–364.
   PubMed Web of Science ®Google Scholar
• Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19–28.
   PubMed Web of Science ®Google Scholar
• Posch F, Ay C, Stoger H, et al. Exposure to vitamin K antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost. 2019;3(2):207–216.
   PubMed Web of Science ®Google Scholar
• Siltari A, Vapaatalo H. Vascular calcification, vitamin K and warfarin therapy – possible or plausible connection? Basic Clin Pharmacol Toxicol. 2018;122(1):19–24.
   PubMed Web of Science ®Google Scholar
• van Gorp RH, Schurgers LJ. New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs). Nutrients. 2015;7(11):9538–9557.
   PubMed Web of Science ®Google Scholar
• Wheeler D, Giugliano R, Rangaswami J. Anticoagulation-related nephropathy. J Thromb Haemost. 2016;14(3):461–467.
   PubMed Web of Science ®Google Scholar
• Hernandez AV, Bradley G, Khan M, et al. Rivaroxaban versus warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. Eur Heart J Qual Care Clin Outcomes. 2020;6(4):301–307.
   PubMed Web of Science ®Google Scholar
• GWT-TUD GmbH, ClinStat GmbH [Internet]. Factor XA – Inhibition in renal patients with non-valvular atrial fibrillation – Observational registry (XARENO). [cited 8 June 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT02663076.
   Google Scholar
• Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015;65(23):2481–2493.
   PubMed Web of Science ®Google Scholar
• Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: Insights from ROCKET AF. Circulation. 2016;134(1):37–47.
   PubMed Web of Science ®Google Scholar
• Badve SV, Palmer SC, Hawley CM, et al. Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrol Dial Transplant. 2016;31(9):1425–1436.
   PubMed Web of Science ®Google Scholar
• Hartung EA. Biomarkers and surrogate endpoints in kidney disease. Pediatr Nephrol. 2016;31(3):381–391.
   PubMed Web of Science ®Google Scholar
• Kanda E, Kashihara N, Matsushita K, et al. Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices. Clin Exp Nephrol. 2018;22(6):1446–1475.
   PubMed Web of Science ®Google Scholar
• Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and European Medicines Agency. Am J Kidney Dis. 2020;75(1):84–104.
   PubMed Web of Science ®Google Scholar
• Samra M, Abcar AC. False estimates of elevated creatinine. Perm J. 2012;16(2):51–52.
   PubMedGoogle Scholar
• Mol PGM, Maciulaitis R, Vetter T. GFR decline as an end point for clinical trials in CKD: a view from Europe. Am J Kidney Dis. 2014;64(6):838–840.
   PubMed Web of Science ®Google Scholar
• Ciani O, Grigore B, Blommestein H, et al. Validity of surrogate endpoints and their impact on coverage recommendations: a retrospective analysis across international health technology assessment agencies. Med Decis Making. 2021;41(4):439–452.
   PubMed Web of Science ®Google Scholar
• Andrade JG, Hawkins NM, Fordyce CB, et al. Variability in non-vitamin K antagonist oral anticoagulants dose adjustment in atrial fibrillation patients with renal dysfunction: the influence of renal function estimation formulae. Can J Cardiol. 2018;34(8):1010–1018.
   PubMed Web of Science ®Google Scholar
• Camm AJ, GARFIELD-AF Investigators, Cools F, Virdone S, et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol. 2020;76(12):1425–1436.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Shrader P, Thomas L, et al. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol. 2016;68(24):2597–2604.
   PubMed Web of Science ®Google Scholar
• Santos J, António N, Rocha M, et al. Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. Br J Clin Pharmacol. 2020;86(3):533–547.
   PubMed Web of Science ®Google Scholar
• Bristol Myers Squibb, Pfizer EEIG. Eliquis (apixaban) Summary of Product Characteristics. Uxbridge: UK; 25 May 2021. [cited 8 June 2021] Available from: https://www.ema.europa.eu/documents/product-information/eliquis-epar-product-information_en.pdf.
   Google Scholar
• Daiichi Sankyo Europe GmbH. Lixiana (edoxaban) Summary of Product Characteristics. Munich: Germany; 23 April 2021. [cited 8 June 2021] Available from: https://www.ema.europa.eu/documents/product-information/lixiana-epar-product-information_en.pdf.
   Google Scholar
• Boehringer Ingelheim International GmbH. Pradaxa (dabigatran etexilate) Summary of Product Characteristics. Ingelheim am Rhein: Germany; 17 March 2021. [cited 8 June 2021] Available from: https://www.ema.europa.eu/documents/product-information/pradaxa-epar-product-information_en.pdf.
   Google Scholar
• Hijazi Z, Hohnloser SH, Andersson U, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation in relation to renal function over time: Insights from the ARISTOTLE randomized clinical trial. JAMA Cardiol. 2016;1(4):451–460.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Rassen JA, Glynn RJ, et al. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012;12:180.
   PubMed Web of Science ®Google Scholar